NewAmsterdam Pharma Co. NV () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Keros Therapeutics, Inc.

Innoviva, Inc.

Collegium Pharmaceutical, Inc.

Ardelyx, Inc.

NewAmsterdam Pharma Co. NV

REGENXBIO, Inc.

Revance Therapeutics, Inc.

Pharvaris NV

ACELYRIN, Inc.

POINT Biopharma Global, Inc.

Intercept Pharmaceuticals, Inc.

Why is NewAmsterdam Pharma Co. NV ?

Negative results in Jun 25

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 92.11%, its profits have fallen by -1%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is NewAmsterdam Pharma Co. NV for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

NewAmsterdam Pharma Co. NV

79.43%

1.50

70.35%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

161.20%

EBIT Growth (5y)

-463.80%

EBIT to Interest (avg)

-83.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

0.07

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.91

EV to EBIT

-7.70

EV to EBITDA

-7.70

EV to Capital Employed

-47.08

EV to Sales

30.82

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-21.54%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

NET SALES(Q)

At USD 19.14 MM has Grown at 740.06%

RAW MATERIAL COST(Y)

Fallen by -0.6% (YoY

PRE-TAX PROFIT(Q)

At USD -19.95 MM has Grown at 58.72%

NET PROFIT(Q)

At USD -19.95 MM has Grown at 58.72%

EPS(Q)

Highest at USD -0.15

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for NewAmsterdam Pharma Co. NV

Net Sales

At USD 19.14 MM has Grown at 740.06%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (USD MM)

Pre-Tax Profit

At USD -19.95 MM has Grown at 58.72%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -19.95 MM has Grown at 58.72%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.15

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by -0.6% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales